# Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

> **NCT04552288** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 51 (actual)

## Conditions studied

- Solid Tumor
- Solid Carcinoma
- Solid Tumor, Adult
- Hematologic Malignancy

## Interventions

- **DRUG:** Benralizumab

## Key facts

- **NCT ID:** NCT04552288
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-16
- **Primary completion:** 2024-07-19
- **Final completion:** 2027-03-16
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04552288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04552288, "Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04552288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*